Skip to content

Efficacy evaluation of transabdominal diaphragmatic hiatus approach and combined thoracoabdominal approach in the treatment of Siewert type ? esophagogastric junction adenocarcinoma-propensity matching analysis

Efficacy evaluation of transabdominal diaphragmatic hiatus approach and combined thoracoabdominal approach in the treatment of Siewert type ? esophagogastric junction adenocarcinoma-propensity matching analysis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053164
Enrollment
Unknown
Registered
2021-11-13
Start date
2021-11-20
Completion date
Unknown
Last updated
2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma of the esophagogastric junction

Interventions

Group A:Transabdominal hiatus (TH) approach
Group B:Combined thoracoabdominal approach

Sponsors

The First Medical Center of the Chinese People's Liberation Army General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Postoperative precise pathological examination confirmed the diagnosis of AEG; 2. The tumor center is located within the range of 1cm from the dentate line to 2cm below the dentate line (according to the findings of gastroscopy and postoperative specimens); 3. The surgical approach is the transabdominal diaphragmatic hiatus approach or the combined thoracoabdominal approach; 4. No history of other malignant tumors in the past, it is primary AEG; 5. No history of esophageal and gastric surgery (including endoscopic surgery); 6. The patient's preoperative and postoperative examination results, surgical records, and pathological data are complete.

Exclusion criteria

Exclusion criteria: 1. Preoperative examination results suggest that there is metastasis to other organs; 2. During the operation, it was found that the tumor invaded surrounding tissues and organs or peritoneal metastasis (M1); 3. Emergency surgery or only exploratory surgery or palliative resection; 4. Patients with cardiopulmonary insufficiency and severe liver and kidney disease; 5. Patients with malignant tumors of other organs and preoperative neoadjuvant therapy; 6. ASA score > 3 points.

Design outcomes

Primary

MeasureTime frame
Overall survival;

Countries

China

Contacts

Public ContactWang Xinxin

The First Medical Center of the Chinese People's Liberation Army General Hospital

301wangxx@sina.com+86 10 66968328

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026